Novartis Ag (NVS) Profit After Tax (2009 - 2026)
Novartis Ag (NVS) posted Profit After Tax of $3.3 billion for Q2 2026, down 19.06% sequentially from $4.0 billion in Q2 2025, and down 19.06% YoY from $4.0 billion in Q2 2025.
Novartis Ag (NVS) Profit After Tax (2009 - 2026) Analysis & Trends
Novartis Ag has reported Profit After Tax for 18 years, with the latest figure at $3.3 billion in Q2 2026.
- Quarterly Profit After Tax fell 19.06% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.5 billion (down 7.6% YoY) and the FY2025 annual result came in at $14.0 billion, up 16.99% from the prior year.
- Profit After Tax declined to $3.3 billion in Q2 2026 per NVS's latest filing, from $4.0 billion in the prior quarter.
- Over five years, Profit After Tax peaked at $34001.4 billion in Q1 2022 and troughed at $1.1 billion in Q3 2022.
- A 5-year average of $3548.4 billion and a median of $3.9 billion in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax surged 142.84% in 2022, then tumbled 85.29% in 2023.
- Over 5 years, Profit After Tax stood at $3.9 billion in 2022, then rose by 17.81% to $4.6 billion in 2023, then gained by 28.69% to $5.9 billion in 2024, then tumbled by 32.19% to $4.0 billion in 2025, then slipped by 19.06% to $3.3 billion in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $3.3 billion, $4.0 billion, and $5.9 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -248.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 438.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.26 Bn |
| Jun 30, 2025 | 4.02 Bn |
| Dec 31, 2024 | 5.93 Bn |
| Jun 30, 2024 | 3.25 Bn |
| Dec 31, 2023 | 4.61 Bn |
| Jun 30, 2023 | 2.32 Bn |
| Mar 31, 2023 | 5,001.33 Bn |
| Dec 31, 2022 | 3.91 Bn |
| Sep 30, 2022 | 1.14 Bn |
| Jun 30, 2022 | 1.70 Bn |
| Mar 31, 2022 | 34,001.37 Bn |
| Dec 31, 2021 | 4.95 Bn |
| Sep 30, 2021 | 1.40 Bn |
| Jun 30, 2021 | 2.90 Bn |
| Mar 31, 2021 | 14,001.31 Bn |
| Dec 31, 2020 | 4.04 Bn |
| Sep 30, 2020 | 18,001.39 Bn |
| Jun 30, 2020 | 1.87 Bn |
| Mar 31, 2020 | 194.00 Mn |
| Jun 30, 2019 | 6.80 Bn |